Marc de Garidel, Abivax CEO
October 20, 2023 11:07 AM EDTUpdated 12:03 PM
Financing

French biotech Abi­vax makes Nas­daq de­but, aim­ing to raise $236M to get PhI­II da­ta in IBD

Andrew Dunn

Senior Biopharma Correspondent

Abi­vax start­ed trad­ing Fri­day on the Nas­daq, as the decade-old Paris-based start­up aims to raise about $236 mil­lion to get Phase III re­sults for its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Evotec gains on Halozyme's takeover pro­pos­al

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times